A comparison of drug-eluting stents versus bare metal stents in saphenous vein graft PCI outcomes: A meta-analysis

Journal of Interventional Cardiology

Volumn 24, Issue 2, 2011, Pages 172-180

  Mamas, Mamas A ^a,b   Foley, James ^a   Nair, Satheesh ^a   Wiper, Andrew ^a   Clarke, Bernard ^a   El Omar, Magdi ^a   Fraser, Douglas G ^a   Khattar, Rajdeep ^a   Neyses, Ludwig ^a,b   Fath Ordoubadi, Farzin ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ARTICLE; BARE METAL STENT; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; SAPHENOUS VEIN GRAFT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; HUMANS; SAPHENOUS VEIN; STENTS; TREATMENT OUTCOME;

EID: 79953747742     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2010.00620.x     Document Type: Article

References (40)

1. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive metaanalysis of randomized trials and observational studies. Circulation 2009;119(25):3198-3206.
2. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356(10):1030-1039. (Pubitemid 46376803)
3. Fitzgibbon G, Kafka H, Leach A, et al. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-626. (Pubitemid 26288642)
4. Campeau L, Lesperance J, Hermann J, et al. Loss of the improvement of angina between 1 and 7 years after aortocoronary bypass surgery: Correlation with changes in vein grafts and in coronary arteries. Circulation 1979;60:1-5.
5. Baim DS. Percutaneous treatment of saphenous vein graft disease: The ongoing challenge. J Am Coll Cardiol 2003;42(8):1370-1372. (Pubitemid 37267274)
6. Vermeersch P, Agostoni P, Verheye S, et al.; DELAYED RRISC Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007;50(3):261-267. (Pubitemid 47039289)
7. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009;53(11):919-928.
8. Gioia G, Benassi A, Mohendra R, et al. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 2008;72(1):13-20. (Pubitemid 352008974)
9. Assali A, Raz Y, Vaknin-Assa H, et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. EuroIntervention 2008;4(1):108-114.
10. Okabe T, Lindsay J, Buch AN, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 2008;102(5):530-534.
11. Bansal D, Muppidi R, Singla S, et al. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv 2008;71(1):58-61. (Pubitemid 351158347)
12. van Twisk PH, Daemen J, Kukreja N, et al. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. EuroIntervention 2008;4(3):311-317.
13. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97(1):34-37. (Pubitemid 41828119)
14. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66(4):507-511. (Pubitemid 41779016)
15. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005;45(7):989-994. (Pubitemid 40432427)
16. Ramana RK, RonanA, Cohoon K, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 2008;71(7):886-893. (Pubitemid 351951305)
17. Applegate RJ, Sacrinty M, Kutcher M, et al. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis. Catheter Cardiovasc Interv 2008;72(1):7-12. (Pubitemid 352013502)
18. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol 2008;101(7):947-952.
19. Rodés-Cabau J, Bertrand OF, Larose E, et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment ofmoderate nonsignificant saphenous vein graft lesions: The Moderate Vein Graft Lesion Stenting With The Taxus Stent And Intravascular Ultrasound (VELETI) pilot trial. Circulation 2009;120(20):1978-1986.
20. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Lancet 1999;354:1896-1900.
21. Stroup DF, Berlin JA, Morton SC, et al.; for the Meta-analysis Of Observational Studies in Epidemiology Group. Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA 2000;283:2008-2012. (Pubitemid 30214957)
22. Voudris V, Kalianos C, Patsilinakos S, et al. Effectiveness of drug-eluting stents in the treatment of bypass graft lesions. Eur Heart J 2006;S27:925.
23. Hoffmann R, Tilmann P, Köster p, et al. Implantation of paclitaxel-eluting stents in saphenous vein grafts: Clinical and angiographic follow up results from a multicentre study. Heart 2007;93:331-334.
24. Wöhrle J, Nusser T, Kestler HA, et al. Comparison of the slow-release polymer-based paclitaxel-eluting taxus-express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007;96(2):70-76. (Pubitemid 46233208)
25. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: Results of a multicenter 350-patient case-control study. J Invasive Cardiol 2007;19(10):404-409. (Pubitemid 47509462)
26. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J IntervCardiol 2007;20(6):458-465. (Pubitemid 350179467)
27. Kanei Y, Sharma J, Diwan R, et al. Long-term outcome of drug-eluting stents in saphenous vein graft lesions. Cardiovasc Revascularization Med 2008;9(3):215.
28. Latib F, Cosgrave G, Romagnoli I, et al. A comparison of the long-term (2 year) safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts. Eur Heart J 2008;S29:455-456.
29. Lozano I, García-Camarero T, Carrillo P, et al. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results.Rev EspCardiol 2009;62(1):39-47.
30. Nair SB, Fath-Ordoubadi F, Clarke B, et al. Late outcomes of drug eluting and bare metal stents in saphenous vein graft percutaneous coronary intervention. EuroIntervention 2010; In Press.
31. Shishehbor MH, Hawi R, Singh IM, et al. Drug-eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J 2009 Oct;158(4):637-643.
32. Brodie BR, Wilson H, Stuckey T, et al.; STENT Group. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv 2009;2(11):1105-1112.
33. Ribichini F, Pugno F, Ferrero V, et al. Long-term histological and immunohistochemical findings in human venous aortocoronary bypass grafts. Clin Sci (Lond) 2008;114(3):211-220. (Pubitemid 351293996)
34. Van Beusekom H, Van Der Giessen W, Van Suylen R, et al. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993;21:45-54. (Pubitemid 23031294)
35. Ribichini F, Pugno F, Ferrero V, et al. Angiotensin-converting enzyme tissue activity in the diffuse in-stent restenotic plaque. Circulation 2000;101:e33-e35.
36. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48(1):193-202. (Pubitemid 43929240)
37. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94(6):1247-1254.
38. Sidhu MS, Brown JR, Yang RC, et al.; Dartmouth Dynamic Registry Investigators. Real world, long-term outcomes comparison between paclitaxel-eluting and sirolimus-eluting stent platforms. J Interv Cardiol 2010;23(2):167-175.
39. Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: Long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010;5(8):898-905.
40. Novack V, Cutlip D, Kleiman N, et al. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: Results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2009;2(8):767-775.